R. James Kasinger's Insider Trades & SAST Disclosures
R. James Kasinger's most recent trade in CRISPR Therapeutics AG was a trade of 6,250 Common Shares done . Disclosure was reported to the exchange on March 20, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern R. James Kasinger.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2025 | 6,250 | 84,914 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2025 | 6,250 | 18,750 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 41.23 per share. | 20 Mar 2025 | 3,185 | 81,729 (0%) | 0% | 41.2 | 131,318 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 36,666 | 36,666 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 27,500 | 27,500 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 5,500 | 11,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 5,500 | 80,380 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 42.42 per share. | 10 Mar 2025 | 2,850 | 77,530 (0%) | 0% | 42.4 | 120,897 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 2,250 | 0 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 2,250 | 79,780 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 43.32 per share. | 10 Mar 2025 | 1,116 | 78,664 (0%) | 0% | 43.3 | 48,345 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2025 | 20,000 | 0 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2025 | 20,000 | 82,597 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 53.85 per share. | 16 Feb 2025 | 9,595 | 73,002 (0%) | 0% | 53.9 | 516,691 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2025 | 3,825 | 3,825 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2025 | 3,825 | 76,827 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 52.80 per share. | 16 Feb 2025 | 1,947 | 74,880 (0%) | 0% | 52.8 | 102,802 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2024 | 30,000 | 30,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2024 | 18,333 | 18,333 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2024 | 2,113 | 4,227 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2024 | 2,113 | 63,686 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 46.28 per share. | 13 Oct 2024 | 1,089 | 62,597 (0%) | 0% | 46.3 | 50,399 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2024 | 33,333 | 33,333 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2024 | 25,000 | 25,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 5,500 | 16,500 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 5,500 | 62,871 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 78.26 per share. | 10 Mar 2024 | 2,801 | 60,070 (0%) | 0% | 78.3 | 219,206 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 2,250 | 2,250 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 2,250 | 62,320 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 74.44 per share. | 10 Mar 2024 | 1,146 | 61,174 (0%) | 0% | 74.4 | 85,308 | Common Shares |
| CRISPR Therapeutics AG | Kasinger James R. | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 3,825 | 59,284 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 3,825 | 7,650 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | R. James Kasinger | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 79.67 per share. | 18 Feb 2024 | 1,913 | 57,371 (0%) | 0% | 79.7 | 152,409 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 22,000 | 22,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 2,833 | 54,899 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 2,833 | 0 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 2,250 | 4,500 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 2,250 | 55,866 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.22 per share. | 10 Mar 2023 | 1,283 | 53,616 (0%) | 0% | 43.2 | 55,451 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.22 per share. | 10 Mar 2023 | 1,022 | 54,844 (0%) | 0% | 43.2 | 44,171 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2023 | 3,825 | 54,016 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2023 | 3,825 | 11,475 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 48.26 per share. | 18 Feb 2023 | 1,950 | 52,066 (0%) | 0% | 48.3 | 94,107 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2022 | 6,667 | 0 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2022 | 6,667 | 53,425 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.26 per share. | 03 Dec 2022 | 3,234 | 50,191 (0%) | 0% | 52.3 | 169,009 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2022 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2022 | 20,000 | 20,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 2,834 | 2,833 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 2,834 | 46,539 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 2,250 | 6,750 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 2,250 | 47,468 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.56 per share. | 10 Mar 2022 | 1,321 | 45,218 (0%) | 0% | 62.6 | 82,642 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 61.08 per share. | 10 Mar 2022 | 1,039 | 46,429 (0%) | 0% | 61.1 | 63,462 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 34,200 | 34,200 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 15,300 | 15,300 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2021 | 13,333 | 49,845 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2021 | 13,333 | 6,667 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 69.17 per share. | 03 Dec 2021 | 6,303 | 43,542 (0%) | 0% | 69.2 | 435,979 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Oct 2021 | 10,800 | 10,800 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2021 | 10,000 | 33,911 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Sale or transfer of securities back to the company at price $ 0.00 per share. | 10 Sep 2021 | 10,000 | 0 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 117.86 per share. | 10 Sep 2021 | 4,741 | 29,170 (0%) | 0% | 117.9 | 558,774 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 25,360 | 25,360 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 9,000 | 9,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 2,833 | 25,264 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 124.15 per share. | 10 Mar 2021 | 1,353 | 23,911 (0%) | 0% | 124.2 | 167,975 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2021 | 27,500 | 12,500 | - | - | Stock Option (right to buy) | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 51.49 per share. | 19 Jan 2021 | 27,500 | 49,931 (0%) | 0% | 51.5 | 1,415,975 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 205.60 per share. | 19 Jan 2021 | 8,997 | 26,331 (0%) | 0% | 205.6 | 1,849,783 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 204.40 per share. | 19 Jan 2021 | 7,818 | 35,328 (0%) | 0% | 204.4 | 1,597,999 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 203.58 per share. | 19 Jan 2021 | 6,785 | 43,146 (0%) | 0% | 203.6 | 1,381,290 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 207.61 per share. | 19 Jan 2021 | 2,100 | 22,431 (0%) | 0% | 207.6 | 435,981 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 206.05 per share. | 19 Jan 2021 | 1,800 | 24,531 (0%) | 0% | 206.1 | 370,890 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.62 per share. | 09 Dec 2020 | 22,026 | 22,415 (0%) | 0% | 13.6 | 299,994 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2020 | 22,026 | 100,974 | - | - | Stock Option (right to buy) | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2020 | 11,666 | 11,666 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges